Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Net Cash Flow (2018 - 2025)

UroGen Pharma (URGN) has disclosed Net Cash Flow for 8 consecutive years, with $20.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 56.01% year-over-year to $20.7 million, compared with a TTM value of -$61.0 million through Dec 2025, down 178.93%, and an annual FY2025 reading of -$61.0 million, down 178.93% over the prior year.
  • Net Cash Flow was $20.7 million for Q4 2025 at UroGen Pharma, up from -$2.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $99.2 million in Q3 2023 and bottomed at -$94.8 million in Q3 2024.
  • Average Net Cash Flow over 5 years is $2.9 million, with a median of -$9.5 million recorded in 2021.
  • The sharpest move saw Net Cash Flow tumbled 551.35% in 2022, then skyrocketed 639.49% in 2024.
  • Year by year, Net Cash Flow stood at -$11.0 million in 2021, then soared by 343.45% to $26.7 million in 2022, then plummeted by 190.93% to -$24.3 million in 2023, then skyrocketed by 293.72% to $47.1 million in 2024, then crashed by 56.01% to $20.7 million in 2025.
  • Business Quant data shows Net Cash Flow for URGN at $20.7 million in Q4 2025, -$2.6 million in Q3 2025, and -$11.1 million in Q2 2025.